Methods of treating metabolic disorders with dual function fibroblast growth factor 21 proteins
US10669323B2 · kind B2 · utility
3Cited by
7References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 26, 2016 |
| Grant date | Jun 2, 2020 |
| Priority date | — |
| Expiry date | Aug 26, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/75
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the identification of dual function fusion proteins comprising fibroblast growth factor 21 (FGF21) and Exenatide, Exendin-4, or GLP-1. Also disclosed are methods for treating metabolic, cardiovascular, and endocrine conditions related to glucose and/or lipid homeostasis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.